Clear Labs Raises $60MM in Series C Financing to Accelerate Breakthrough Approach that Identifies Pathogens, including SARS-CoV-2 and Its Variants, in Real-Time

SAN CARLOS, Calif.: SAN CARLOS, Calif., May 26, 2021 /PRNewswire-PRWeb/ -- Clear Labs, provider of the only fully automated, next-generation sequencing (NGS) platform for turnkey diagnostics, has secured $60 million in Series C funding. The financing was co-led by new investors Counterpoint Global (Morgan Stanley) and funds and accounts advised...

Click to view original post